RxDoctor Payments Data

Paul Papadimitriou, MD

Psychiatry · Wheeling, WVNPI 1801909510

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 53.3% of the total. Reporting peaked in 2019 at $370 and has fallen 64.7% since, to $131 in 2023.

$832in general payments, 2019–2025

Across 56 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$444
  • Sunovion Pharmaceuticals Inc.$97
  • Alkermes, Inc.$92
  • Johnson & Johnson$75
  • Vanda Pharmaceuticals Inc.$44
  • Otsuka America Pharmaceutical, Inc.$38
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$832100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$832 in reported general payments places this provider in the 70th percentile of 177 psychiatry providers in West Virginia.

See all psychiatry providers in West Virginia

Medicare billing

Part B allowed, 2024
$24,626
Medicare patients
98
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$110,398
Lurasidone Hcl40$16,910
TrintellixVortioxetine Hydrobromide14$9,237
BelsomraSuvorexant13$5,885
Duloxetine Hcl223$4,065
Mirtazapine183$2,730
Quetiapine Fumarate152$2,669
Clonazepam382$2,336
Fluvoxamine Maleate12$1,704
Oxcarbazepine34$1,682
Venlafaxine Hcl ErVenlafaxine Hcl118$1,570
Buspirone Hcl88$1,472
Trazodone Hcl148$1,355
Lamotrigine103$1,335
Bupropion XlBupropion Hcl115$1,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$31$110,39814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 177 psychiatry providers in West Virginia.

Other psychiatry in Wheeling

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →